TY - JOUR
T1 - Antibiotic Consumption During the Coronavirus Disease 2019 Pandemic and Emergence of Carbapenemase-Producing Klebsiella pneumoniae Lineages Among Inpatients in a Chilean Hospital
T2 - A Time-Series Study and Phylogenomic Analysis
AU - Allel, Kasim
AU - Peters, Anne
AU - Conejeros, Jose
AU - Martínez, Jose R.W.
AU - Spencer-Sandino, Maria
AU - Riquelme-Neira, Roberto
AU - Rivas, Lina
AU - Rojas, Pamela
AU - Orellana Chea, Cristian
AU - García, Patricia
AU - Araos, Rafael
AU - Mcgovern, Olivia
AU - Patel, Twisha S.
AU - Arias, Cesar A.
AU - Lessa, Fernanda C.
AU - Undurraga, Eduardo A.
AU - Munita, Jose M.
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PY - 2023/7/5
Y1 - 2023/7/5
N2 - BACKGROUND: The impact of coronavirus disease 2019 (COVID-19) on antimicrobial use (AU) and resistance has not been well evaluated in South America. These data are critical to inform national policies and clinical care.METHODS: At a tertiary hospital in Santiago, Chile, between 2018 and 2022, subdivided into pre- (3/2018-2/2020) and post-COVID-19 onset (3/2020-2/2022), we evaluated intravenous AU and frequency of carbapenem-resistant Enterobacterales (CRE). We grouped monthly AU (defined daily doses [DDD]/1000 patient-days) into broad-spectrum β-lactams, carbapenems, and colistin and used interrupted time-series analysis to compare AU during pre- and post-pandemic onset. We studied the frequency of carbapenemase-producing (CP) CRE and performed whole-genome sequencing analyses of all carbapenem-resistant (CR) Klebsiella pneumoniae (CRKpn) isolates collected during the study period.RESULTS: Compared with pre-pandemic, AU (DDD/1000 patient-days) significantly increased after the pandemic onset, from 78.1 to 142.5 (P < .001), 50.9 to 110.1 (P < .001), and 4.1 to 13.3 (P < .001) for broad-spectrum β-lactams, carbapenems, and colistin, respectively. The frequency of CP-CRE increased from 12.8% pre-COVID-19 to 51.9% after pandemic onset (P < .001). The most frequent CRE species in both periods was CRKpn (79.5% and 76.5%, respectively). The expansion of CP-CRE harboring blaNDM was particularly noticeable, increasing from 40% (n = 4/10) before to 73.6% (n = 39/53) after pandemic onset (P < .001). Our phylogenomic analyses revealed the emergence of two distinct genomic lineages of CP-CRKpn: ST45, harboring blaNDM, and ST1161, which carried blaKPC.CONCLUSIONS: AU and the frequency of CP-CRE increased after COVID-19 onset. The increase in CP-CRKpn was driven by the emergence of novel genomic lineages. Our observations highlight the need to strengthen infection prevention and control and antimicrobial stewardship efforts.
AB - BACKGROUND: The impact of coronavirus disease 2019 (COVID-19) on antimicrobial use (AU) and resistance has not been well evaluated in South America. These data are critical to inform national policies and clinical care.METHODS: At a tertiary hospital in Santiago, Chile, between 2018 and 2022, subdivided into pre- (3/2018-2/2020) and post-COVID-19 onset (3/2020-2/2022), we evaluated intravenous AU and frequency of carbapenem-resistant Enterobacterales (CRE). We grouped monthly AU (defined daily doses [DDD]/1000 patient-days) into broad-spectrum β-lactams, carbapenems, and colistin and used interrupted time-series analysis to compare AU during pre- and post-pandemic onset. We studied the frequency of carbapenemase-producing (CP) CRE and performed whole-genome sequencing analyses of all carbapenem-resistant (CR) Klebsiella pneumoniae (CRKpn) isolates collected during the study period.RESULTS: Compared with pre-pandemic, AU (DDD/1000 patient-days) significantly increased after the pandemic onset, from 78.1 to 142.5 (P < .001), 50.9 to 110.1 (P < .001), and 4.1 to 13.3 (P < .001) for broad-spectrum β-lactams, carbapenems, and colistin, respectively. The frequency of CP-CRE increased from 12.8% pre-COVID-19 to 51.9% after pandemic onset (P < .001). The most frequent CRE species in both periods was CRKpn (79.5% and 76.5%, respectively). The expansion of CP-CRE harboring blaNDM was particularly noticeable, increasing from 40% (n = 4/10) before to 73.6% (n = 39/53) after pandemic onset (P < .001). Our phylogenomic analyses revealed the emergence of two distinct genomic lineages of CP-CRKpn: ST45, harboring blaNDM, and ST1161, which carried blaKPC.CONCLUSIONS: AU and the frequency of CP-CRE increased after COVID-19 onset. The increase in CP-CRKpn was driven by the emergence of novel genomic lineages. Our observations highlight the need to strengthen infection prevention and control and antimicrobial stewardship efforts.
KW - Antibiotic consumption
KW - Antimicrobial resistance
KW - COVID-19
KW - Carbapenemase-producing organisms
KW - Klebsiella pneumoniae
KW - Carbapenems/pharmacology
KW - Pandemics
KW - Colistin
KW - Humans
KW - Chile/epidemiology
KW - Klebsiella pneumoniae/genetics
KW - Phylogeny
KW - beta-Lactams
KW - Anti-Bacterial Agents/pharmacology
KW - Anti-Infective Agents
KW - Microbial Sensitivity Tests
KW - Inpatients
KW - Carbapenem-Resistant Enterobacteriaceae
KW - COVID-19/epidemiology
KW - Bacterial Proteins/genetics
KW - Hospitals
KW - beta-Lactamases/genetics
UR - http://www.scopus.com/inward/record.url?scp=85163940906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85163940906&partnerID=8YFLogxK
U2 - 10.1093/cid/ciad151
DO - 10.1093/cid/ciad151
M3 - Article
C2 - 37406053
AN - SCOPUS:85163940906
SN - 1058-4838
VL - 77
SP - S20-S28
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - Suppl 1
ER -